Latest Novo Nordisk Stories
Market Size - $1,326.6 Mn 2013, Market Growth - CAGR of 16.2%, Market Trends –Innovations such as ultra-long acting analogs new report by Grand View Research.
Latest delivery device advancement in the basal insulin category PLAINSBORO, N.J., June 19, 2014 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, today announced the availability
Global Type 1 Diabetes Market 2014-2018 a research report available at ReportsnReports.com. Dallas, Texas (PRWEB) June 18, 2014 The key vendors in the
The Diabetes Advocacy Alliance(TM) Urges Congress to Pass the National Diabetes Clinical Care Commission Act This Congressional Session WASHINGTON, June 18, 2014 /PRNewswire-USNewswire/
SAN FRANCISCO, June 14, 2014 /PRNewswire/ -- Data from a new phase 3 study demonstrated that once-daily Victoza(R) (liraglutide [rDNA origin] injection) provided greater
SAN FRANCISCO, June 14, 2014 /PRNewswire/ -- New Phase 3a findings show IDegLira, the investigational once-daily single injection combination of insulin degludec and liraglutide,
Data also showed liraglutide 3 mg improved blood glucose control compared to placebo at 56 weeks SAN FRANCISCO, June 14, 2014 /PRNewswire/ -- Today, primary results
Diabetes leader nominated by Plainsboro's Mayor Peter Cantu PLAINSBORO, N.J., June 6, 2014 /PRNewswire/ -- Novo Nordisk, a global health care company with more than 90 years of innovation
MISSISSAUGA, ON, June 4, 2014 /CNW/ - Novo Nordisk today announces that the Québec government has approved the inclusion of Victoza(®) (liraglutide), the first once-daily human glucagon-like
Market Size - $4.9 bn in 2013, Market Growth - CAGR of 17.6%, Market Trends – Substitution of human insulin by analogs new report by Grand View Research.
- The act of sweetening by admixture of some saccharine substance.